Clinical trial
A Phase I/II Trial of Ruxolitinib in Chronic Lymphocytic Leukemia Patients at Risk for Progression on Ibrutinib
NCT02912754 is registered in ClinicalTrials.gov with Sunnybrook Health Sciences Centre as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I/II Trial of Ruxolitinib in Chronic Lymphocytic Leukemia Patients at Risk for Progression on Ibrutinib
- Lead sponsor
- Sunnybrook Health Sciences Centre
- Phase
- Phase 1/2
- Overall status
- Unknown status
- Start date
- March 31, 2017
- Completion date
- August 31, 2019
- Enrollment
- 36 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.